Katherine Stueland Sells 6,325 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 6,325 shares of GeneDx stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $11.04, for a total value of $69,828.00. Following the sale, the chief executive officer now directly owns 75,869 shares in the company, valued at $837,593.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Katherine Stueland also recently made the following trade(s):

• On Monday, March 18th, Katherine Stueland sold 8,559 shares of GeneDx stock. The shares were sold at an average price of $10.59, for a total value of $90,639.81.

GeneDx Trading Up 22.6 %

NASDAQ WGS opened at $20.92 on Thursday. The company has a market cap of $545.05 million, a price-to-earnings ratio of -4.04 and a beta of 2.75. GeneDx Holdings Corp. has a 52 week low of $1.16 and a 52 week high of $21.49. The business has a 50 day moving average price of $9.63 and a 200-day moving average price of $5.19. The company has a quick ratio of 2.95, a current ratio of 3.10 and a debt-to-equity ratio of 0.23.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, February 20th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.01. GeneDx had a negative return on equity of 34.40% and a negative net margin of 60.86%. The firm had revenue of $57.42 million during the quarter, compared to the consensus estimate of $57.00 million. As a group, equities analysts expect that GeneDx Holdings Corp. will post -2.02 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeneDx

Several institutional investors have recently bought and sold shares of WGS. Oracle Investment Management Inc. boosted its position in GeneDx by 14.9% in the third quarter. Oracle Investment Management Inc. now owns 994,580 shares of the company’s stock worth $3,620,000 after purchasing an additional 128,731 shares during the last quarter. Decheng Capital LLC purchased a new position in GeneDx in the fourth quarter worth $285,000. Trellus Management Company LLC boosted its position in GeneDx by 55.0% in the third quarter. Trellus Management Company LLC now owns 155,012 shares of the company’s stock worth $564,000 after purchasing an additional 54,976 shares during the last quarter. Pathstone Family Office LLC boosted its position in GeneDx by 262.2% in the third quarter. Pathstone Family Office LLC now owns 54,327 shares of the company’s stock worth $198,000 after purchasing an additional 39,327 shares during the last quarter. Finally, HighTower Advisors LLC boosted its position in GeneDx by 14.1% in the third quarter. HighTower Advisors LLC now owns 237,948 shares of the company’s stock worth $865,000 after purchasing an additional 29,361 shares during the last quarter. Institutional investors own 61.72% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on WGS shares. TD Cowen lifted their price objective on GeneDx from $14.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday. The Goldman Sachs Group lifted their target price on GeneDx to $11.00 and gave the stock a “neutral” rating in a report on Monday, April 15th. Finally, BTIG Research lifted their target price on GeneDx from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Tuesday.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.